{"id":16890,"date":"2024-03-19T13:47:46","date_gmt":"2024-03-19T04:47:46","guid":{"rendered":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/?page_id=16890"},"modified":"2026-01-08T16:16:27","modified_gmt":"2026-01-08T07:16:27","slug":"results","status":"publish","type":"page","link":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/department\/shinryoka\/hinyou\/results\/","title":{"rendered":"\u6ccc\u5c3f\u5668\u79d1 \u81e8\u5e8a\u7814\u7a76\u767a\u8868\u5b9f\u7e3e"},"content":{"rendered":"\n

\u5e73\u621028\u5e74\u5ea6\uff5e\u5e73\u62106\u5e74\u5ea6<\/h2>\n\n\n\n

\u4ee4\u548c6\u5e74\u5ea6<\/h3>\n\n\n\n

\u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n

    \n
  1. Shiota M\u3001Takamatsu D\u3001Matsui Y\u3001Yokomizo A\u3001Morizane S\u3001Saito R\u3001Miyake M\u3001Tsutsumi M\u3001Yamamoto Y\u3001Tashiro K\u3001Tomida R\u3001Narita S\u3001Edamura K\u3001Yamaguchi T\u3001 Hashimoto K\u3001 Kato M\u3001Kasahara T\u3001Yoshino T\u3001Akamatsu S\u3001Kaneko T\u3001Matsukawa A\u3001Matsumoto R\u3001Joraku A\u3001Saito T\u3001Kato T\u3001Kato M\u3001Enokida H\u3001Sakamoto S\u3001Terada N\u3001Kanno H\u3001Nishiyama N\u3001Kimura T\u3001Kitamura H\u3001Eto M; Japanese Urological Oncology Group.Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy. Ann Surg Oncol\u3001 2024\u00a0 Jun;31(6):3872-3879\u3001 doi: 10\u30011245\/s10434-024-14999-2\u3001 Epub 2024 Feb 14\u3001<\/li>\n\n\n\n
  2. Sakamoto S\u3001Sato K\u3001Kimura T\u3001Matsui Y\u3001Shiraishi Y\u3001Hashimoto K\u3001Miyake H\u3001NaritaS\u3001Miki J\u3001Matsumoto R\u3001Kato T\u3001Saito T\u3001Tomida R\u3001Shiota M\u3001Joraku A\u3001Terada N\u3001Suekane S\u3001 Kaneko T\u3001 Tatarano S\u3001Yoshio Y\u3001Yoshino T\u3001Nishiyama N\u3001Kawakami E\u3001Ichikawa T\u3001Kitamura H.\u3000PSA doubling time 4\u300165 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer.\u3000Sci Rep\u30012024 Jul 3;14(1):15307\u3001doi: 10\u30011038\/s41598-024-65969-3\u3001<\/li>\n\n\n\n
  3. Tanegashima T\u3001Shiota M\u3001Kimura T\u3001Takamatsu D\u3001Matsui Y\u3001Yokomizo A\u3001Saito R\u3001 Morizane S\u3001Miyake M\u3001Tsutsumi M\u3001Yamamoto Y\u3001Tashiro K\u3001Tomida R\u3001Edamura K\u3001Narita S\u3001Yamaguchi T\u3001Kasahara T\u3001Hashimoto K\u3001Kato M\u3001Yoshino T\u3001Akamatsu S\u3001 Matsukawa A\u3001Kaneko T\u3001Matsumoto R\u3001Joraku A\u3001Kato M\u3001Saito T\u3001Kato T\u3001Tatarano S\u3001Sakamoto S\u3001Kanno H\u3001Terada N\u3001Nishiyama N\u3001Kitamura H\u3001Eto M; Japanese Urological Oncology Group.\u3000Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement.\u3000Int J Clin Oncol\u30012024 Oct;29(10):1586-1593\u3001doi: 10\u30011007\/s10147-024-02580-6\u3001Epub 2024 Jul 8<\/li>\n<\/ol>\n\n\n\n

    \u4ee4\u548c5\u5e74\u5ea6<\/h3>\n\n\n\n

    \u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n

      \n
    1. Minami K\u3001 Osawa T\u3001 Kojima T\u3001 Hara T\u3001 Eto M\u3001 Takeuchi A\u3001 Nakai Y\u3001Ueda K\u3001 Ozawa M\u3001 Uemura M\u3001 Ohba K\u3001 Tamura K\u3001 Shindo T\u3001 Nakagomi H\u3001 Takahashi A\u3001 Anai S\u3001 Yokomizo A\u3001 Morizane S\u3001 Kimura T\u3001 Shimazui T\u3001 Miyauchi Y\u3001 Mitsuzuka K\u3001 Hara H\u3001 Yoshimura K\u3001 Shiina H\u3001 Ito YM\u3001 Murai S\u3001 Nishiyama H\u3001 Shinohara N\u3001 Kitamura H; Japanese Urological Oncology Group. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment. Urol Oncol. 41(11):458.e9-458.e19\u3001 2023<\/li>\n<\/ol>\n\n\n\n

      \u4ee4\u548c4\u5e74\u5ea6<\/h3>\n\n\n\n

      \u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n

        \n
      1. Tanaka T, Joraku A, Ishibashi S, Endo K, Emura M, Kikuchi Y, Shikama A, Kimura N, Shimazui T. Abdominal nonfunctional paraganglioma in which succinate dehydrogenase subunit B (SDHB) immunostaining was performed: a case report. J Med Case Rep. 2023 Mar 22;17(1):106. doi: 10.1186\/s13256-023-03822-3. PMID: 36945070; PMCID: PMC10031891.<\/li>\n\n\n\n
      2. Kita Y, Ito K, Kanda S, Joraku A, Yamaguchi R, Shimizu Y, Hayata N, Somiya S, Shibasaki N, Kimura T, Hikami K, Yamada T, Abe T, Tsuchihashi K, Tatarano S, Nishiyama H, Kitamura H, Kobayashi T. Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction. Urol Oncol. 2022 Sep;40(9):410.e11-410.e18. doi: 10.1016\/j.urolonc.2022.04.005. Epub 2022 May 9. PMID: 35551861.<\/li>\n\n\n\n
      3. Shiota M, Takamatsu D, Kimura T, Tashiro K, Matsui Y, Tomida R, Saito R, Tsutsumi M, Yokomizo A, Yamamoto Y, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Narita S, Matsumoto R, Kasahara T, Hashimoto K, Matsumoto H, Kato M, Akamatsu S, Joraku A, Kato M, Yamaguchi T, Saito T, Kaneko T, Takahashi A, Kato T, Sakamoto S, Enokida H, Kanno H, Terada N, Suekane S, Nishiyama N, Eto M, Kitamura H; Japanese Urological Oncology Group. Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer. Cancer Sci. 2022 ul;113(7):2386-2396. doi: 10.1111\/cas.15383. Epub 2022 May 17. PMID: 35485635; PMCID: PMC9277249.<\/li>\n<\/ol>\n\n\n\n

        \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n

          \n
        1. \u611f\u67d3\u6027\u5fc3\u5185\u819c\u708e\u3092\u5408\u4f75\u3057\u305f\u591a\u81d3\u5668\u81bf\u760d\u306e1\u4f8b. \u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u3000\u6ccc\u5c3f\u5668\u79d11\u3001\u5faa\u74b0\u5668\u5185\u79d12. \u91ce\u4e2d\u9065\u59481\u3001\u99ac\u5834\u96c5\u5b502\u3001\u77f3\u6a4b\u5c0f\u767e\u54081\u3001\u9234\u6728\u79c0\u5e731\u3001\u6c5f\u6751\u6b63\u535a1\u3001\u5e38\u6a02\u66431\u3001\u5cf6\u5c45\u5fb91. \u7b2c 70 \u56de \u8328 \u57ce \u814e \u7814 \u7a76 \u4f1a. \u65e5 \u6642\uff1a\u4ee4\u548c 4 \u5e74 5 \u6708 17 \u65e5\uff08\u706b\uff09 (\u4f1a\u5834\uff0bWEB)<\/li>\n\n\n\n
        2. \u5f53\u9662\u3067TIP\u7642\u6cd5\u3092\u65bd\u884c\u3057\u305f\u9670\u830e\u764c\u306e2\u4f8b. \u77f3\u6a4b\u5c0f\u767e\u5408\u3001\u9234\u6728\u79c0\u5e73\u3001\u91ce\u4e2d\u9065\u5948\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e38\u6a02\u6643\u3001\u5cf6\u5c45\u5fb9. \u7b2c123\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a 2022\u5e746\u670818\u65e5\uff08\u4f1a\u5834\uff0bWeb\uff09<\/li>\n\n\n\n
        3. \u30b3\u30ed\u30ca\u798d\u3067\u65bd\u884c\u3055\u308c\u305f\u524d\u7acb\u817a\u751f\u691c\u60a3\u8005\u80cc\u666f\u306e\u691c\u8a0e. \u6c5f\u6751\u6b63\u535a\u3001\u77f3\u6a4b\u5c0f\u767e\u5408\u3001\u91ce\u4e2d\u9065\u5948\u3001\u9234\u6728\u79c0\u5e73\u3001\u5e38\u6a02\u6643\u3001\u5cf6\u5c45\u5fb9. \u7b2c82\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u3000\u6771\u90e8\u7dcf\u4f1a\u30002022\u5e7410\u670828\u65e5\uff08\u8efd\u4e95\u6ca2\uff09<\/li>\n<\/ol>\n\n\n\n

          \u4ee4\u548c3\u5e74\u5ea6<\/h3>\n\n\n\n

          \u3010\u57f7\u7b46\u3011<\/p>\n\n\n\n

            \n
          1. \u5cf6\u5c45\u5fb9\uff1a\u7279\u96c6.\u672c\u90a6\u306e\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u524d\u7acb\u817a\u5168\u6458\u8853\u306e\u3053\u308c\u307e\u3067\u3068\u3053\u308c\u304b\u3089\uff0d\u6a19\u6e96\u8853\u5f0f\u3068\u5909\u6cd5\u3001\u62e1\u5927\u5207\u9664\u3001\u65b0\u898f\u30ed\u30dc\u30c3\u30c8\u306b\u3064\u3044\u3066\uff0d\u5e8f\u6587.\u6ccc\u5c3f\u5668\u5916\u79d1\u300034\uff1a347-347, 2021.<\/li>\n<\/ol>\n\n\n\n

            \u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n

              \n
            1. Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H, Eto M; Japanese Urological Oncology Group (JUOG). Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci. 2021 Apr;112(4):1524-1533. doi: 10.1111\/cas.14722. Epub 2021 Feb 13.PMID: 33159829 <\/li>\n\n\n\n
            2. Nakai Y, Takeuchi A, Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Minami K, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Morizane S, Kawasaki Y, Morooka D, Shimazui T, Yamamoto Y, Nakagomi H, Tomida R, Ito YM, Murai S, Kitamura H, Nishiyama H, Shinohara N; Japanese Urological Oncology Group. Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma. .J Geriatr Oncol. 2021 Jun;12(5):834-837. doi: 10.1016\/j.jgo.2020.12.012. Epub 2020 Dec 31.PMID: 33388281<\/li>\n\n\n\n
            3. Shiota M, Terada N, Kitamura H, Kojima T, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Sugimoto M, Mizowaki T, Kamoto T, Nishiyama H, Eto M; Japanese Urological Oncology Group. Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer. Cancer Sci. 2021 Sep;112(9):3616-3626. doi: 10.1111\/cas.15038. Epub 2021 Jul 10.PMID: 34145921<\/li>\n\n\n\n
            4. Nishiyama N, Kobayashi T, Narita S, Hidaka Y, Ito K, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Kojima T, Morita S, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching. J Geriatr Oncol. 2022 Jan;13(1):88-93. doi: 10.1016\/j.jgo.2021.07.002. Epub 2021 Jul 6.PMID: 34238726<\/li>\n\n\n\n
            5. Kobayashi T, Ito K, Kojima T, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Ogawa O, Kitamura H, Nishiyama H. Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR. Cancer Immunol Immunother. 2022 Feb;71(2):461-471. doi: 10.1007\/s00262-021-03000-8. Epub 2021 Jul 7.PMID: 34235546<\/li>\n\n\n\n
            6. Endo K, Joraku A, Kawai K, Ikeda A, Kimura T, Ishitsuka R, Kandori S, Waku N, Hoshi A, Kojima T, Amano T, Hara T, Nasu K, Minami M, Nishiyama H. [False-Positive \u00b9\u00b2\u00b3I-Metaiodobenzylguanidine Scan in a Patient with Adrenocortical Cancer]. Hinyokika Kiyo. 2021 Nov;67(11):483-488. Japanese. doi:10.14989\/ActaUrolJap_67_11_483. PMID: 34856786.<\/li>\n\n\n\n
            7. Hamada K, Joraku A, Ichioka D, Emura M, Shimazui T. [Renal Mucinous Tubular and Spindle Cell Carcinoma : A Case Report]. Hinyokika Kiyo. 2021 Jun;67(6):233-238. Japanese. doi: 10.14989\/ActaUrolJap_67_6_233. PMID: 34265898.<\/li>\n<\/ol>\n\n\n\n

              \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n

                \n
              1. \u6c5f\u6751\u6b63\u535a\u3001\u963f\u90e8\u60a0\u6597\u3001\u7530\u4e2d\u9686\u9020\u3001\u9060\u85e4\u6176\u7950\u3001\u5e38\u6a02\u6643\u3001\u5cf6\u5c45\u5fb9\uff0e\u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u306b\u304a\u3051\u308b\u524d\u7acb\u817a\u80a5\u5927\u75c7\u306b\u5bfe\u3059\u308b\u7d4c\u5c3f\u9053\u7684\u524d\u7acb\u817a\u6838\u51fa\u8853\uff08TUEB\uff09\u306e\u521d\u671f\u7d4c\u9a13.\u7b2c81\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u3000\u6771\u90e8\u7dcf\u4f1a\u30002021\u5e749\u67084\u65e5\u3000(web)<\/li>\n\n\n\n
              2. \u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u306b\u304a\u3051\u308b\u814e\u304c\u3093\u306e\u85ac\u7269\u7642\u6cd5. 2021\u5e7410\u670814\u65e5\u3000IO-IO RCC Web Live Seminar(web)<\/li>\n\n\n\n
              3. \u77f3\u6a4b\u5c0f\u767e\u5408\u3001\u7530\u4e2d\u9686\u9020\u3001\u9060\u85e4\u6176\u7950\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e38\u697d\u3000\u6643\u3001\u5cf6\u5c45\u3000\u5fb9\uff1a\u53bb\u52e2\u62b5\u6297\u6027\u524d\u7acb\u817a\u304c\u3093\u6cbb\u7642\u4e2d\u306b\u80ba\u8ee2\u79fb\u3092\u6765\u3057\u305f\u75c7\u4f8b\uff0e\u7b2c121\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u30002021\u5e7410\u670817\u65e5\uff08web\u958b\u50ac\uff09<\/li>\n\n\n\n
              4. \u6c0f\u5bb6\u90c1\u5f25\u3001\u77f3\u4e95\u3000\u8475\u3001\u5ddd\u53c8\u5ba3\u592b\u3001\u4ed9\u6ce2\u670b\u7f8e\u3001\u4e2d\u7530\u516c\u7f8e\u3001\u9ad8\u7530\u6e05\u5b50\u3001\u77f3\u6a4b\u5c0f\u767e\u5408\u3001\u7530\u4e2d\u9686\u9020\u3001\u9060\u85e4\u6176\u7950\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e38\u697d\u3000\u6643\u3001\u5cf6\u5c45\u3000\u5fb9\uff1a\u524d\u7acb\u817a\u5168\u6458\u8853\u5f8c\u306e\u8179\u5727\u6027\u5c3f\u5931\u7981\u306b\u5bfe\u3059\u308b\u53d6\u308a\u7d44\u307f\uff0e\u7b2c33\u56de\u8328\u57ce\u6ccc\u5c3f\u5668\u75be\u60a3\u30b1\u30a2\u7814\u7a76\u4f1a\u30002021\u5e7411\u670820\u65e5(web\u3001\u3064\u304f\u3070)<\/li>\n\n\n\n
              5. \u7530\u4e2d\u9686\u9020\u3001\u77f3\u6a4b\u5c0f\u767e\u5408\u3001\u9060\u85e4\u6176\u7950\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e38\u697d\u3000\u6643\u3001\u5cf6\u5c45\u3000\u5fb9\u3001\u83ca\u6c60\u7950\u4ecb\u3001\u5fd7\u938c\u660e\u4eba\uff1a\u5f8c\u8179\u819c\u975e\u6a5f\u80fd\u6027\u30d1\u30e9\u30ac\u30f3\u30b0\u30ea\u30aa\u30fc\u30de\u306e1\u4f8b\uff0e\u7b2c122\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u30002022\u5e742\u67085\u65e5\uff08web\u958b\u50ac\u3001\u963f\u898b\uff09<\/li>\n<\/ol>\n\n\n\n

                \u4ee4\u548c2\u5e74\u5ea6<\/h3>\n\n\n\n

                \u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n

                  \n
                1. Ito K, Kobayashi M, Komiyama M, Naito S, Nishimura K, Yonese J, Hashine K, Saito S, Arai G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, Takezawa Y, Fujimoto H, Yokomizo A, Kakimoto K, Fukui I, Karasawa K, Tsukamoto T, Nozaki M, Hasumi M, Ishiyama H, Ohtani M, Kuwahara M, Harada M, Ohashi Y, Kotake T, Kakizoe T, Suzuki K, Yamanaka H, National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer Investigators Affiliations. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous\/intermittent endocrine therapy in an open-label, randomized, phase 3 trial. Cancer 126(17):3961-3971\u30012020<\/li>\n\n\n\n
                2. Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y, Ikeshiro S, Nakagomi H, Morita K, Tomida R, Mochizuki T, Inoue T, Kitamura H, Yamada S, Ito YM, Murai S, Nishiyama H, Shinohara N, Japanese Urological Oncology Group: Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. Cancer Sci. 111(7):2460-2471. 2020<\/li>\n\n\n\n
                3. Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H, Eto M; Japanese Urological Oncology Group (JUOG): Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci. 2020 Nov 7 Online ahead of print.PMID: 33159829<\/li>\n\n\n\n
                4. Nakai Y, Takeuchi A, Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Minami K, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Morizane S, Kawasaki Y, Morooka D, Shimazui T, Yamamoto Y, Nakagomi H, Tomida R, Ito YM, Murai S, Kitamura H, Nishiyama H, Shinohara N; Japanese Urological Oncology Group: Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma. J Geriatr Oncol. S1879-4068(20)30534-8 . 2020 Online ahead of print.PMID: 33388281<\/li>\n<\/ol>\n\n\n\n

                  \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n

                    \n
                  1. \u6c5f\u6751\u6b63\u535a\u3001\u6ff1\u7530\u548c\u5e0c\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u5e38\u6a02\u6643\u3001\u77f3\u9ed2\u614e\u543e\u3001\u5cf6\u5c45\u5fb9. \u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u306b\u304a\u3051\u308b\u30ab\u30d0\u30b8\u30bf\u30ad\u30bb\u30eb\uff08\uff23\uff22\uff3a\uff09\u7642\u6cd5\u306e\u6cbb\u7642\u7d4c\u9a13. \u7b2c 108 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012020.12(\u795e\u6238\/Web)<\/li>\n\n\n\n
                  2. \u963f\u90e8\u60a0\u6597\u3001\u7530\u4e2d\u9686\u9020\u3001\u9060\u85e4\u6176\u7950\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e38\u6a02\u6643\u3001\u5cf6\u5c45\u5fb9. \u5de6\u814e\u306b\u767a\u751f\u3057\u305f\u708e\u75c7\u6027\u507d\u816b\u760d\u306e\u4e00\u4f8b. \u7b2c 119 \u56de \u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u30012021.2 (\u9f8d\u30b1\u5d0e\/WEB)<\/li>\n<\/ol>\n\n\n\n

                    \u3010\u53d7\u8cde\u3011<\/p>\n\n\n\n

                      \n
                    1. \u4e45\u7530\u8cde \u9280\u8cde\uff08Annals of Nuclear Medicine \u8ad6\u6587\u8cde\uff09. Joraku A, Hatano K, Kawai K, Kandori S, Kojima T, Fukumitsu N, Isobe T, Mori Y, Sakata M, Hara T, Nasu K, Minami M, Iizumi Y, Nishiyama H. Phase I\/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies. \u53d7\u8cde\u8b1b\u6f14 2020.11 \uff08\u795e\u6238\uff09<\/li>\n<\/ol>\n\n\n\n

                      \u4ee4\u548c\u5143\u5e74<\/h3>\n\n\n\n

                      \u3010\u8457\u66f8\u3011<\/p>\n\n\n\n

                        \n
                      1. \u5cf6\u5c45 \u5fb9 (\u62c5\u5f53:\u5206\u62c5\u57f7\u7b46, \u7bc4\u56f2:\u5468\u8853\u671f\u306e\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u4e88\u9632) 20.\u8840\u6813\u585e\u6813\u75c7 In\uff1a\u6ccc\u5c3f\u5668\u79d1\u85ac\u7269\u7642\u6cd5 \u6ccc\u5c3f\u5668\u79d1 vol.32 \u7279\u5225\u53f7 \u533b\u5b66\u56f3\u66f8\u51fa\u7248 2019<\/li>\n<\/ol>\n\n\n\n

                        \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n

                          \n
                        1. \u5cf6\u5c45 \u5fb9\u3001\u6ff1\u7530\u548c\u5e0c\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5c71\u5185 \u6566\u3001\u5e38\u6a02 \u6643\uff0e\u9ad8\u96e3\u5ea6\u75c7\u4f8b\u306b\u5bfe\u3059\u308b\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u814e\u90e8\u5206\u5207\u9664\u8853\u306e\u691c\u8a0e\uff0e\u7b2c 107 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012019.4\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n\n\n\n
                        2. \u6c5f\u6751\u6b63\u535a\u3001\u6ff1\u7530\u548c\u5e0c\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u5e38\u6a02 \u6643\u3001\u7389\u6728\u7fa9\u96c4\u3001\u5cf6\u5c45 \u5fb9\uff0e\u5f53\u9662\u3067\u306e\u524d\u7acb\u817a\u5168\u6458\u8853\u5f8c\u751f\u5316\u5b66\u7684\u518d\u767a\u306b\u5bfe\u3059\u308b\u6551\u6e08\u653e\u5c04\u7dda\u6cbb\u7642\u306e\u6cbb\u7642\u6210\u7e3e\uff0e\u7b2c 107 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012019.4\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n\n\n\n
                        3. \u5e02\u5ca1\u5927\u58eb\u3001\u6ff1\u7530\u548c\u5e0c\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e38\u6a02 \u6643\u3001\u5cf6\u5c45 \u5fb9\uff0e\u5c3f\u8def\u4e0a\u76ae\u764c\u306b\u5bfe\u3059\u308b\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u5206\u5272 GC\u7642\u6cd5\u306e\u691c\u8a0e\uff0e\u7b2c 107 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012019.4\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n\n\n\n
                        4. \u6ff1\u7530\u548c\u5e0c\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e38\u6a02 \u6643\u3001\u5c71\u5185 \u6566\u3001\u5cf6\u5c45 \u5fb9\uff0e\u9ad8\u96e3\u5ea6\u75c7\u4f8b\u306b\u5bfe\u3059\u308b\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u814e\u90e8\u5206\u5207\u9664\u8853\u306e\u691c\u8a0e\uff0e\u7b2c 107 \u56de \u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012019.4\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n\n\n\n
                        5. \u6ff1\u7530\u548c\u5e0c\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e38\u6a02 \u6643\u3001\u5c71\u5185 \u6566\u3001\u5cf6\u5c45 \u5fb9\uff0e\u814e\u6a5f\u80fd\u4f4e\u4e0b\u75c7\u4f8b\u306b\u5bfe\u3059\u308b\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u814e\u90e8\u5206\u5207\u9664\u8853\u5f8c\u306e\u691c\u8a0e\uff0e\u7b2c 66 \u56de \u8328\u57ce\u814e\u7814\u7a76\u4f1a\u30012019.5\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n
                        6. \u6ff1\u7530\u548c\u5e0c\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e38\u6a02 \u6643\u3001\u5cf6\u5c45 \u5fb9\uff0e\u814e\u7c98\u6db2\u7ba1\u72b6\u7d21\u9318\u7d30\u80de\u764c\u306e\uff11\u4f8b\uff0e\u7b2c 115 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u30012019.10\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n
                        7. \u6ff1\u7530\u548c\u5e0c\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e38\u6a02 \u6643\u3001\u5cf6\u5c45 \u5fb9\uff0e\u5f53\u9662\u306b\u304a\u3051\u308b\u7d4c\u5f8c\u8179\u819c\u30a2\u30d7\u30ed\u30fc\u30c1\u306b\u3088\u308b\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u524d\u7acb\u817a\u5168\u6458\u8853\u306e\u691c\u8a0e\uff0e\u7b2c 116 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u30012020.2\uff08\u571f\u6d66\uff09<\/li>\n<\/ol>\n\n\n\n

                          \u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n

                            \n
                          1. \u5cf6\u5c45\u5fb9\uff0e\u524d\u7acb\u817a\u304c\u3093\uff0d\u751f\u6d3b\u7fd2\u6163\u30fb\u691c\u8a3a\u30fb\u6cbb\u7642\u306e\u6700\u8fd1\u306e\u8a71\u984c\uff0d\uff0e \u7b20\u9593\u5e02\u5e02\u6c11\u516c\u958b\u8b1b\u5ea7\u30012019.12\uff08\u7b20\u9593\uff09<\/li>\n\n\n\n
                          2. \u6c5f\u6751\u6b63\u535a\uff0e\u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u306b\u304a\u3051\u308b\u30ab\u30d0\u30b8\u30bf\u30ad\u30bb\u30eb\uff08\uff23\uff22\uff3a\uff09\u7642\u6cd5\u306e\u6cbb\u7642\u7d4c\u9a13\uff0e\u3064\u304f\u3070\u524d\u7acb\u817a\u304c\u3093\u5316\u5b66\u7642\u6cd5\u8b1b\u6f14\u4f1a\u30012019.11\uff08\u3064\u304f\u3070\uff09<\/li>\n<\/ol>\n\n\n\n

                            \u5e73\u621030\u5e74\u5ea6<\/h3>\n\n\n\n

                            \u3010\u548c\u6587\u539f\u8457\u3011<\/p>\n\n\n\n

                              \n
                            1. \u9234\u6728\u79c0\u5e73\uff0c\u5c71\u5185 \u6566\uff0c\u6c5f\u6751\u6b63\u535a\uff0c\u8fbb\u672c\u4e00\u5e73\uff0c\u5e02\u5ca1\u5927\u58eb\uff0c\u5927\u8c37\u5e79\u4f38\uff0c\u5cf6\u5c45\u5fb9\uff1a\u6458\u51fa\u8853\u5f8c\u77ed\u671f\u9593\u306b\u518d\u767a\u30fb\u6025\u901f\u5897\u5927\u3092\u7e70\u308a\u8fd4\u3057\u305f\u5f8c\u8179\u819c\u8102\u80aa\u8089\u816b\u306e 1 \u4f8b\uff0c\u6ccc\u5c3f\u5668\u5916\u79d1 31:975-979.2018<\/li>\n\n\n\n
                            2. \u4f50\u91ce\u5553\u4ecb\uff0c\u6728\u6751\u53cb\u548c\uff0c\u6cb3\u5408\u5f18\u4e8c\uff0c\u6c60\u7530\u7be4\u53f2\uff0c\u77f3\u585a\u7adc\u592a\u90ce\uff0c\u795e\u9ce5\u5468\u4e5f\uff0c\u548c\u4e45\u590f\u8863\uff0c\u661f\u662d\u592b\uff0c\u5c0f\u5cf6\u5d07\u5b8f\uff0c\u5e38\u6a02\u6643\uff0c\u6a4b\u672c\u8ad2\u5178\uff0c\u897f\u5c71\u535a\u4e4b\uff1a\u7570\u6642\u6027\u306b\u30de\u30f3\u30c8\u30eb\u7d30\u80de\u30ea\u30f3\u30d1\u816b\u3092\u767a\u75c7\u3057\u305f\u75c5\u671f I \u30bb\u30df\u30ce\u30fc\u30de \u306e 1 \u4f8b\uff0c\u6ccc\u5c3f\u5668\u79d1\u7d00\u8981\uff0c64(12): 509-513\u30012018<\/li>\n\n\n\n
                            3. \u6ff1\u7530\u548c\u5e0c\uff0c\u77f3\u585a\u7adc\u592a\u90ce\uff0c\u6cb3\u5408\u5f18\u4e8c\uff0c\u5fd7\u8cc0\u6b63\u5ba3\uff0c\u7530\u4e2d\u5065\uff0c\u6c60\u7530\u7be4\u53f2\uff0c\u5409\u91ce\u55ac\u4e4b\uff0c\u6cb3\u539f\u8cb4\u53f2\uff0c\u795e\u70cf\u5468\u4e5f\uff0c\u6728\u6751\u53cb\u548c\uff0c\u548c\u4e45\u590f\u8863\uff0c\u661f\u662d\u592b\uff0c\u5c0f\u5cf6\u5d07\u5b8f\uff0c\u5e38\u6a02\u6643\uff0c\u4f50\u85e4\u6cf0\u6a39\uff0c\u9808\u6469\u685c\u5b50\uff0c\u5742\u7530\u9ebb\u5b9f\u5b50\uff0c\u5c0f\u539f\u76f4\uff0c\u4f0a\u85e4\u5b5d\u7f8e\uff0c\u897f\u5c71\u535a\u4e4b \uff1a \u814e\u5b5f\u5c3f\u7ba1\u58c1\u306e\u8457\u660e\u306a\u80a5\u539a\u3092\u793a\u3057\u305f Mucosa-associated lymphoid tissue\u3000(MALT)\u30ea\u30f3\u30d1\u816b\u306e 1 \u4f8b\uff1a \u6ccc\u5c3f\u5668\u79d1\u7d00\u8981 64(12): 489-495\uff0c2018<\/li>\n<\/ol>\n\n\n\n

                              \u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n

                                \n
                              1. Shimazui T, Yoshikawa K, Ishitsuka R, Kojima T, Kandori S, Yoshino T, Miyazaki J, Uchida K, Nishiyama H. Systemic transduction of p16(INK4a) antitumor peptide inhibits lung metastasis of the MBT-2 bladder tumor cell line in mice. Oncol Lett. 17:1203-1210. 2019<\/li>\n\n\n\n
                              2. Kandori S, Kojima T, Matsuoka T, Yoshino T, Sugiyama A, Nakamura E, Shimazui T, Funakoshi Y, Kanaho Y, Nishiyama H. Phospholipase D2 promotes disease progression of renal cell carcinoma through the induction of angiogenin Cancer Science 109:1865- 1875.2018<\/li>\n\n\n\n
                              3. Inada K, Okoshi Y, Cho-Isoda Y, Ishiguro S, Suzuki H, Oki A, Tamaki Y, Shimazui T, Saito H, Hori M, Iijima T, Kojima H. Endogenous reference RNAs for microRNA quantitation in formalinfixed, paraffin-embedded lymph node tissue Scientific Reports 8(1):5918-5927, 2018<\/li>\n\n\n\n
                              4. Kurobe M, Kawai K, Suetomi T, Iwamoto T, Waku N, Kawahara T, Kojima T, Joraku A, Miyazaki J, Nishiyama H. High prevalence of hypogonadism determined by serumfree testosterone level in Japanese testicular cancer survivors. Int J Urol. 25(5):457-462.2018<\/li>\n\n\n\n
                              5. Joraku A, Hatano K, Kawai K, Kandori S, Kojima T, Fukumitsu N, Isobe T, Mori Y, Sakata M, Hara T, Nasu K, Minami M, Iizumi Y, Nishiyama H. Phase I\/IIa PETimaging study with (89)zirconium labeled anti-PSMA minibody for urological malignancies. Ann Nucl Med. 33(2):119-127. 2018<\/li>\n<\/ol>\n\n\n\n

                                \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n

                                  \n
                                1. \u6728\u540d\u702c\u8061\u83ef\u3001\u6ff1\u7530\u548c\u5e0c\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e38\u697d\u6643\u3001\u5cf6\u5c45\u5fb9. \u5897\u5927\u50be\u5411\u3092\u793a\u3057\u305f\u5de6\u7cbe\u5de3\u56a2\u80de\u306e1 \u4f8b. \u7b2c 113 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u30012019.2\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n
                                2. \u5cf6\u5c45\u5fb9\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u6ff1\u7530\u548c\u5e0c\u3001\u9234\u6728\u79c0\u5e73\u3001\u5c71\u5185\u6566\u3001\u5e38\u697d\u6643\uff1a\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u814e\u90e8\u5206\u5207\u9664\u8853\u521d\u671f\u75c7\u4f8b\u306e Pentafecta \u306b\u95a2\u3059\u308b\u691c\u8a0e\uff0e\u7b2c 32 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u7dcf\u4f1a\u30012018.11\uff08\u4ed9\u53f0\uff09<\/li>\n\n\n\n
                                3. \u5cf6\u5c45\u5fb9. \u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u8180\u80f1\u5168\u6458\u8853\u306e\u521d\u671f\u6210\u7e3e\u3068\u624b\u6280\uff0e\u8328\u57ce\u6ccc\u5c3f\u5668\u624b\u8853\u624b\u6280\u7814\u7a76\u4f1a 2018\u30012018.11\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n
                                4. \u4e2d\u7530\u516c\u7f8e\u3001\u5927\u5cf6\u7f8e\u5948\u5b50\u3001\u6ff1\u7530\u548c\u5e0c\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u4f50\u3005\u6728\u660e\u3001\u5e38\u697d\u6643\u3001\u5cf6\u5c45\u5fb9. \u9000\u9662\u5f8c \u8a2a\u554f\u6307\u5c0e\u306e\u5b9f\u969b\u3068\u4eca\u5f8c\u306e\u8ab2\u984c\uff0e\u7b2c 30 \u56de\u8328\u57ce\u6ccc\u5c3f\u5668\u75be\u60a3\u30b1\u30a2\u7814\u7a76\u4f1a\u30012018.11\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n
                                5. \u6ff1\u7530\u548c\u5e0c\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e38\u6a02\u6643\u3001\u5cf6\u5c45\u5fb9. \u6c17\u816b\u6027\u8180\u80f1\u708e\u306e\uff11\u4f8b\uff0e\u7b2c 112 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1 \u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u30012018.10\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n
                                6. \u5cf6\u5c45\u5fb9. \u6ccc\u5c3f\u5668\u79d1\u624b\u8853\u306b\u304a\u3051\u308b VTE\uff0d\u4e88\u9632\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3068\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\uff0d. \u6ccc\u5c3f\u5668\u79d1\u9023\u643a\u8b1b\u6f14\u4f1a \uff5e\u304c\u3093\u3068\u8840\u6813\u3092\u8003\u3048\u308b\uff5e\u30012018.9\uff08\u5e02\u539f\uff09<\/li>\n\n\n\n
                                7. \u9234\u6728\u79c0\u5e73\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u5e38\u6a02\u6643\u3001\u6ff1\u7530\u548c\u5e0c\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5c71\u5185\u6566. \u6065\u9aa8\u4e0a\u90e8\u306e\u76ae\u4e0b\u8edf\u90e8\u7d44\u7e54\u306b\u8ee2\u79fb\u3092\u304d\u305f\u3057\u305f\u524d\u7acb\u817a\u764c\u306e\uff11\u4f8b. \u7b2c 111 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u30012018.6\uff08\u7b20\u9593\uff09<\/li>\n\n\n\n
                                8. \u6ff1\u7530\u548c\u5e0c\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e38\u6a02\u6643\u3001\u5cf6\u5c45\u5fb9. \u4e21\u5074\u814e\u816b\u760d\u3092\u5951\u6a5f\u306b\u8a3a\u65ad\u3055\u308c\u305f\u9ac4\u5916\u6027\u5f62\u8cea\u7d30\u80de\u816b\u306e\uff11\u4f8b. \u7b2c 64 \u56de\u8328\u57ce\u814e\u7814\u7a76\u4f1a\u30012018.6\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n
                                9. \u6c5f\u6751\u6b63\u535a\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u5c71\u5185\u6566\u3001\u5cf6\u5c45\u5fb9\u3001\u5927\u8c37\u5e79\u4f38\u3001\u7389\u6728\u7fa9\u96c4. \u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u306b\u304a\u3051\u308b\u53bb\u52e2\u62b5\u6297\u6027\u524d\u7acb\u817a\u304c\u3093\uff08CRPC)\u306b\u5bfe\u3059\u308b\u30e9\u30b8\u30a6\u30e0 223(223Ra)\u6295\u4e0e\u306e\u521d\u671f\u7d4c\u9a13. \u7b2c 106 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1 \u5b66\u4f1a\u7dcf\u4f1a\u30012018.4\uff08\u4eac\u90fd\uff09<\/li>\n\n\n\n
                                10. \u5c71\u5185\u6566\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5cf6\u5c45\u5fb9\u3001\u5927\u8c37\u5e79\u4f38. \u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u3067\u306e\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u524d\u7acb\u817a\u5168\u6458\u8853\u306b\u304a\u3051\u308b\u62e1\u5927\u30ea\u30f3\u30d1\u7bc0\u90ed\u6e05\u306b\u3064\u3044\u3066\u306e\u81e8\u5e8a\u7684\u691c\u8a0e. \u7b2c 106 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012018.4\uff08\u4eac\u90fd\uff09<\/li>\n\n\n\n
                                11. \u6c5f\u6751\u6b63\u535a\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u5c71\u5185\u6566\u3001\u5cf6\u5c45\u5fb9\u3001\u5927\u8c37\u5e79\u4f38\u3001\u5150\u5c71\u5065. \u5c0f\u5f84\u814e\u764c\u306b\u5bfe\u3059\u308b\u7d4c\u76ae\u7684\u51cd\u7d50\u7642\u6cd5\u304c\u814e\u6a5f\u80fd\u306b\u53ca\u307c\u3059\u5f71\u97ff. \u7b2c 106 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012018.4 (\u4eac\u90fd)<\/li>\n<\/ol>\n\n\n\n

                                  \u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n

                                    \n
                                  1. \u5e38\u6a02\u6643. \u524d\u7acb\u817a\u764c\u306e\u8a3a\u65ad\u3068\u6cbb\u7642\u306b\u3064\u3044\u3066. \u524d\u7acb\u817a\u764c\u30bb\u30df\u30ca\u30fcin \u7b20\u9593\u30012018.1\uff08\u7b20\u9593\uff09<\/li>\n<\/ol>\n\n\n\n

                                    \u5e73\u621029\u5e74\u5ea6<\/h3>\n\n\n\n

                                    \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n

                                      \n
                                    1. \u6c5f\u6751\u6b63\u535a\u3001\u5c71\u5185 \u6566\u3001\u5cf6\u5c45 \u5fb9\u3001\u7389\u6728\u7fa9\u96c4\u3001\u5927\u8c37\u5e79\u4f38\uff0e\u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u306b\u304a\u3051\u308b\u524d\u7acb\u817a\u304c\u3093\u306b\u5bfe\u3059\u308b\u5f37\u5ea6 \u5909\u8abf\u653e\u5c04\u7dda\u6cbb\u7642\u306e\u77ed\u671f\u6210\u7e3e\uff0e\u7b2c 105 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7dcf\u4f1a 2017.4 (\u9e7f\u5150\u5cf6)<\/li>\n\n\n\n
                                    2. \u5c71\u5185 \u6566\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5cf6\u5c45 \u5fb9\u3001\u5927\u8c37\u5e79\u4f38\uff0e\u8328\u57ce\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u306b\u304a\u3051\u308b FDG-PET\/CT \u306e\u524d\u7acb\u817a\u764c\u8a3a\u65ad\u306b\u95a2 \u3059\u308b\u81e8\u5e8a\u7684\u610f\u7fa9\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e\uff0e\u7b2c 105 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7dcf\u4f1a 2017.4 (\u9e7f\u5150\u5cf6)<\/li>\n\n\n\n
                                    3. \u5cf6\u5c45 \u5fb9\u3001\u5c71\u5185 \u6566\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u8fbb\u672c\u4e00\u5e73\u3001\u7530\u4e2d \u5efa\u3001\u5927\u8c37\u5e79\u4f38\u3001\u53e4\u5bb6\u7422\u4e5f\uff0e\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u8180\u80f1 \u5168\u6458\u8853\u306e\u521d\u671f\u7d4c\u9a13\uff0e\u7b2c 108 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a \u7b2c 3 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u6803\u6728\u30fb\u8328\u57ce\u5408\u540c\u5730\u65b9\u4f1a 2017.6 (\u4e0b\u90fd\u8cc0)<\/li>\n\n\n\n
                                    4. \u5c71\u5185 \u6566\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5cf6\u5c45 \u5fb9\u3001\u5927\u8c37\u5e79\u4f38\uff0e\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u7642\u6cd5\u306b\u3088\u308a DIC \u304b\u3089\u96e2\u8131\u3067\u304d\u305f\u53bb\u52e2\u62b5 \u6297\u6027\u524d\u7acb\u817a\u764c\u306e 1 \u4f8b\uff0e\u7b2c 108 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u30fb\u7b2c 3 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u6803\u6728\u30fb\u8328\u57ce\u5408\u540c\u5730 \u65b9\u4f1a 2017.6 (\u4e0b\u90fd\u8cc0)<\/li>\n\n\n\n
                                    5. \u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5c71\u5185 \u6566\u3001\u5cf6\u5c45 \u5fb9\u3001\u5927\u8c37\u5e79\u4f38\u3001\u5150\u5c71 \u5065\uff0e\u5358\u814e\u75c7\u4f8b\u306e\u5c0f\u5f84\u814e\u816b\u760d\u306b\u5bfe\u3059\u308b\u51cd\u7d50\u7642\u6cd5 \u306e\u691c\u8a0e\uff0e\u7b2c 62 \u56de\u8328\u57ce\u814e\u7814\u7a76\u4f1a 2017.6 (\u6c34\u6238)<\/li>\n\n\n\n
                                    6. \u5cf6\u5c45 \u5fb9\u3001\u5c71\u5185 \u6566\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u9234\u6728\u79c0\u5e73\u3001\u5927\u8c37\u5e79\u4f38\uff0e\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u814e\u90e8\u5206\u5207\u9664\u8853\u306e\u77ed\u671f\u6210\u7e3e\u306e \u691c\u8a0e\uff0e\u7b2c 31 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u7dcf\u4f1a 2017.11 (\u5fb3\u5cf6)<\/li>\n\n\n\n
                                    7. \u6c5f\u6751\u6b63\u535a\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u5c71\u5185 \u6566\u3001\u5cf6\u5c45 \u5fb9\u3001\u5927\u8c37\u5e79\u4f38\uff0e\u5f53\u9662\u306b\u304a\u3051\u308b\u524d\u7acb\u817a\u80a5\u5927\u75c7\u306b\u5bfe\u3059\u308b\u5149\u9078\u629e\u7684\u30ec\u30fc\u30b6 \u30fc\u84b8\u6563\u8853\uff08PVP)\u306e\u521d\u671f\u6210\u7e3e\uff0e\u7b2c 31 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u7dcf\u4f1a 2017.11 (\u5fb3\u5cf6)<\/li>\n\n\n\n
                                    8. \u4e2d\u7530\u516c\u7f8e\u3001\u702c\u5c3e\u76f4\u7f8e\u3001\u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5c71\u5185 \u6566\u3001\u5cf6\u5c45 \u5fb9\u3001\u5927\u8c37\u5e79\u4f38\u3001\u4f50\u3005\u6728 \u660e\uff0e\u6392\u6cc4\u30b1\u30a2\u306b\u304a\u3051 \u308b\u30b9\u30bf\u30c3\u30d5\u306e\u610f\u8b58\u6539\u9769\u3092\u76ee\u6307\u3057\u3066 \uff5e\u304a\u3080\u3064\u306e\u5f53\u3066\u65b9\u306e\u7d71\u4e00\uff5e\uff0e\u7b2c 29 \u56de\u8328\u57ce\u6ccc\u5c3f\u5668\u75be\u60a3\u30b1\u30a2\u7814\u7a76\u4f1a 2017.11 (\u6c34\u6238)<\/li>\n\n\n\n
                                    9. \u5e02\u5ca1\u5927\u58eb\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5c71\u5185 \u6566\u3001\u5cf6\u5c45 \u5fb9\u3001\u5927\u8c37\u5e79\u4f38\uff0e\u8180\u80f1\u62e1\u5927\u8853\u5f8c\u8180\u80f1\u816b\u760d\u306e\uff11\u4f8b\uff0e\u7b2c 110 \u56de\u65e5\u672c\u6ccc\u5c3f\u5668 \u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a 2018.2 (\u7a32\u6577)<\/li>\n<\/ol>\n\n\n\n

                                      \u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n

                                        \n
                                      1. \u5e02\u5ca1\u5927\u58eb\uff0e\u9032\u884c\u6027\u5c3f\u8def\u4e0a\u76ae\u764c\u306b\u5bfe\u3059\u308b\u5316\u5b66\u7642\u6cd5\u306e\u73fe\u72b6\uff0e\u770c\u5317\u6ccc\u5c3f\u5668\u61c7\u8a71\u4f1a. 2017. 6\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n
                                      2. \u5927\u8c37\u5e79\u4f38. \u691c\u8a3a\u3068\u8a3a\u65ad. \u6c34\u6238\u5730\u65b9\u304c\u3093\u5e02\u6c11\u30bb\u30df\u30ca\u30fc\uff5e\u304c\u3093\u3092\u77e5\u308d\u3046\uff5e. 2017. 6 (\u6c34\u6238)<\/li>\n\n\n\n
                                      3. \u5927\u8c37\u5e79\u4f38. Opening Remarks. Pfizer RCC Symposium in MITO. 2017. 6 (\u6c34\u6238) 4. \u5927\u8c37\u5e79\u4f38. \u7dcf\u62ec. \u6c34\u6238\u6ccc\u5c3f\u5668\u304c\u3093\u514d\u75ab\u7642\u6cd5\u30bb\u30df\u30ca\u30fc. 2017. 10 (\u6c34\u6238)<\/li>\n<\/ol>\n\n\n\n

                                        \u5e73\u621028\u5e74\u5ea6<\/h3>\n\n\n\n

                                        \u3010\u8ad6\u6587\u3011<\/p>\n\n\n\n

                                          \n
                                        1. \u5cf6\u5c45\u5fb9\uff1aCAB(combined androgen blockade)\u7642\u6cd5.\u3000\u65b0\u524d\u7acb\u817a\u764c\u5b66\u3000\u6700\u65b0\u306e\u57fa\u790e\u7814\u7a76\u3068\u8a3a\u65ad\u30fb\u6cbb\u7642\u3001\u65e5\u672c\u81e8\u5e8a\u793e\u300174(3)\uff1a578-583, 2016.<\/li>\n\n\n\n
                                        2. Kandori S, Yoshino T, Tsutsumi M, Yamauchi A, Ohtani M, Fukuhara Y, Miyanaga N, Miyazaki J, Nishiyama H, Shimazui T. Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study. Prostate Int 4(4):140-144, 2016.<\/li>\n\n\n\n
                                        3. Koie T, Ohyama C, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Yoneyama T, Tobisawa Y, Yamauchi A, Shimazui T, Ohtani M. The feasibility and effectiveness of robot-assisted radical cystectomy after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. Jpn J Clin Oncol 2016. DOI 10.1093\/jjco\/hyw191 [Epub ahead of print]<\/li>\n\n\n\n
                                        4. \u5cf6\u5c45\u5fb9\u3001\u5c71\u5185\u6566\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5927\u8c37\u5e79\u4f38\uff1a\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u524d\u7acb\u817a\u5168\u6458\u8853\u306f\u3069\u3053\u307e\u3067\u666e\u53ca\u3059\u308b\u304b\uff1f \u764c\u3068\u5316\u5b66\u7642\u6cd5\u300144(1):33-36\u3001 2017.<\/li>\n<\/ol>\n\n\n\n

                                          \u3010\u5b66\u4f1a\u767a\u8868\u3011<\/p>\n\n\n\n

                                            \n
                                          1. \u5cf6\u5c45\u5fb9\u3001\u5c71\u5185\u6566\u3001\u8fbb\u672c\u4e00\u5e73\u3001\u7530\u4e2d\u5efa\u3001\u5409\u91ce\u55ac\u4e4b\u3001\u5927\u8c37\u5e79\u4f38. \u6ccc\u5c3f\u5668\u60aa\u6027\u816b\u760d\u306b\u304a\u3051\u308b\u5468\u8853\u671f\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u306e\u4e88\u9632\u306b\u304a\u3051\u308b\u8853\u524d\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u3068\u3057\u3066\u306eD\u30c0\u30a4\u30de\u30fc\u30ab\u30c3\u30c8\u30aa\u30d5\u5024\u306e\u610f\u7fa9\uff08\u7b2c\uff12\u5831\uff09. \u7b2c104\u56de \u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u3001 2016.4\u3000(\u4ed9\u53f0)<\/li>\n\n\n\n
                                          2. \u5e02\u5ca1\u5927\u58eb\u3001 \u5409\u91ce\u55ac\u4e4b\u3001 \u9ad8\u5ca1\u6804\u4e00\u90ce\u3001 \u672b\u5bcc\u5d07\u5f18\u3001\u5c0f\u5cf6\u5d07\u5b8f\u3001\u5e38\u697d\u6643\u3001\u6cb3\u5408\u5f18\u4e8c\u3001\u5cf6\u5c45\u5fb9\u3001\u5824\u96c5\u4e00\u3001\u83ca\u6c60\u5b5d\u6cbb\u3001\u5185\u7530\u514b\u7d00\u3001\u897f\u5c71\u535a\u4e4b\uff0e\u7b51\u6ce2\u5927\u5b66\u95a2\u9023\u65bd\u8a2d\u306b\u304a\u3051\u308b\u53bb\u52e2\u62b5\u6297\u6027\u524d\u7acb\u817a\u764c\u306b\u5bfe\u3059\u308b\u30ab\u30d0\u30b8\u30bf\u30ad\u30bb\u30eb\u6295\u4e0e\u75c7\u4f8b\u306e\u691c\u8a0e. \u7b2c104\u56de\u3000\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012016.4\u3000(\u4ed9\u53f0)<\/li>\n\n\n\n
                                          3. \u5c71\u672c\u5927\u8f14\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5c71\u5185\u6566\u3001\u5cf6\u5c45\u5fb9\u3001\u5927\u8c37\u5e79\u4f38\uff0e\u8180\u80f1B\u7d30\u80de\u30ea\u30f3\u30d1\u816b\u306e1\u4f8b.\u3000\u7b2c105\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u30012016.6\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n
                                          4. \u5e02\u5ca1\u5927\u58eb\u3001\u5409\u91ce\u55ac\u4e4b\u3001\u5bae\u5d0e\u3000\u6df3\u3001\u6cb3\u5408\u5f18\u4e8c\u3001\u5cf6\u5c45\u5fb9\u3001\u5824\u96c5\u4e00\u3001\u83ca\u6c60\u5b5d\u6cbb\u3001\u5185\u7530\u514b\u7d00\u3001\u897f\u5c71\u535a\u4e4b\uff0e\u7b51\u6ce2\u5927\u5b66\u95a2\u9023\u65bd\u8a2d\u306b\u304a\u3051\u308b\u53bb\u52e2\u62b5\u6297\u6027\u524d\u7acb\u817a\u764c\u306b\u5bfe\u3059\u308b\u30ab\u30d0\u30b8\u30bf\u30ad\u30bb\u30eb\u6295\u4e0e\u75c7\u4f8b\u306e\u691c\u8a0e. \u7b2c105\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u30012016.6\uff08\u3064\u304f\u3070\uff09<\/li>\n\n\n\n
                                          5. \u6c5f\u6751\u6b63\u535a\u3001\u5c71\u5185\u6566\u3001\u5cf6\u5c45\u5fb9\u3001\u5927\u8c37\u5e79\u4f38\uff0e\u6b8b\u5b58\u5c3f\u7ba1\u518d\u767a\u304b\u3089\u306e\u6b62\u8840\u306b\u96e3\u6e0b\u3057\u305f\u5de6\u814e\u76c2\u764c\u8853\u5f8c\u306e\uff11\u4f8b.\u3000\u7b2c38\u56de\u8328\u57ce\u533b\u5b66\u4f1a\u6ccc\u5c3f\u5668\u79d1\u5206\u79d1\u4f1a\u30fb\u7b2c106\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u30002016.10\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n
                                          6. \u5c71\u5185\u6566\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5cf6\u5c45\u5fb9\u3001\u5927\u8c37\u5e79\u4f38\uff0e\u8180\u80f1\u764c\u306b\u5bfe\u3057\u30662nd-TURBT\u3092\u65bd\u884c\u3057\u305f\u75c7\u4f8b\u306e\u691c\u8a0e. \u7b2c81\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u6771\u90e8\u7dcf\u4f1a\u30012016.10\uff08\u5f18\u524d\uff09<\/li>\n\n\n\n
                                          7. \u5cf6\u5c45\u5fb9\u3001\u5c71\u5185\u6566\u3001\u8fbb\u672c\u4e00\u5e73\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5927\u8c37\u5e79\u4f38\uff0e\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u8180\u80f1\u5168\u6458\u8853\u306e\u5c0e\u5165\u521d\u671f\u7d4c\u9a13.\u3000\u7b2c81\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u6771\u90e8\u7dcf\u4f1a\u30012016.10\uff08\u5f18\u524d\uff09<\/li>\n\n\n\n
                                          8. \u4e95\u5742\u88d5\u5b50\u3001\u5927\u68ee\u77e5\u5b50\u3001\u5b89\u898b\u304d\u306c\u3044\u3001\u4e2d\u7530\u516c\u7f8e\u3001\u5927\u8c37\u5e79\u4f38\u3001\u5c71\u5185\u6566\u3001\u5cf6\u5c45\u5fb9\u3001\u6c5f\u6751\u6b63\u535a\uff0e\u6392\u5c3f\u81ea\u7acb\u6307\u5c0e\u6599\u52a0\u7b97\u306b\u95a2\u308f\u308b\u75c5\u68df\u306e\u53d6\u308a\u7d44\u307f.\u3000\u7b2c28\u56de\u8328\u57ce\u6ccc\u5c3f\u5668\u75be\u60a3\u30b1\u30a2\u7814\u7a76\u4f1a\u30012016.11\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n
                                          9. \u4e2d\u7530\u516c\u7f8e\u3001\u30a2\u30dc\u30c3\u30c8\u307f\u306e\u308a\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5c71\u5185\u6566\u3001\u5cf6\u5c45\u5fb9\u3001\u5927\u8c37\u5e79\u4f38\u3001\u4f50\u3005\u6728\u660e\u3001\u5bae\u5ddd\u5c1a\u7f8e\uff0e\u6392\u5c3f\u81ea\u7acb\u6307\u5c0e\u306e\u5c0e\u5165\u306b\u5411\u3051\u305f\u53d6\u308a\u7d44\u307f\u3068\u4eca\u5f8c\u306e\u8ab2\u984c\uff0e\u7b2c28\u56de\u8328\u57ce\u6ccc\u5c3f\u5668\u75be\u60a3\u30b1\u30a2\u7814\u7a76\u4f1a\u30012016.11\uff08\u6c34\u6238\uff09<\/li>\n\n\n\n
                                          10. \u6c5f\u6751\u6b63\u535a\u3001\u5c71\u5185\u6566\u3001\u5cf6\u5c45\u5fb9\u3001\u5927\u8c37\u5e79\u4f38\uff0e\u5f53\u79d1\u306b\u304a\u3051\u308b\u8179\u8154\u93e1\u4e0b\u814e\u90e8\u5206\u5207\u9664\u8853\u3068\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u8179\u8154\u93e1\u4e0b\u814e\u90e8\u5206\u5207\u9664\u306e\u6bd4\u8f03.\u7b2c30\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u7dcf\u4f1a\u30012016.11\uff08\u5927\u962a\uff09<\/li>\n\n\n\n
                                          11. \u5cf6\u5c45\u5fb9\u3001\u5c71\u5185\u6566\u3001\u8fbb\u672c\u4e00\u5e73\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5927\u8c37\u5e79\u4f38\u3001\u53e4\u5bb6\u7422\u4e5f\uff0e\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u8180\u80f1\u5168\u6458\u9664\u8853\u306e\u5c0e\u5165\u521d\u671f\u75c7\u4f8b\u306e\u691c\u8a0e.  \u7b2c30\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u5185\u8996\u93e1\u5b66\u4f1a\u7dcf\u4f1a\u3001  2016.11\uff08\u5927\u962a\uff09<\/li>\n\n\n\n
                                          12. \u5c71\u5185\u6566\u3001\u6c5f\u6751\u6b63\u535a\u3001\u5cf6\u5c45\u5fb9\u3001\u5927\u8c37\u5e79\u4f38\uff0e\u5f8c\u8179\u819c\u30a2\u30d7\u30ed\u30fc\u30c1\u6cd5\u306e\u30ed\u30dc\u30c3\u30c8\u652f\u63f4\u524d\u7acb\u817a\u5168\u6458\u8853\u306b\u304a\u3051\u308b\u5de5\u592b. \u7b2c107\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u8328\u57ce\u5730\u65b9\u4f1a\u3001 \u30002017.2\uff08\u3064\u304f\u3070\uff09<\/li>\n<\/ol>\n\n\n\n

                                            \u3010\u8b1b\u6f14\u3011<\/p>\n\n\n\n

                                              \n
                                            1. \u5927\u8c37\u5e79\u4f38. \u6c34\u6238\u5730\u65b9\u304c\u3093\u5e02\u6c11\u30bb\u30df\u30ca\u30fc. 2016.5(\u6c34\u6238)<\/li>\n\n\n\n
                                            2. \u5927\u8c37\u5e79\u4f38. \u7b2c8\u56de\u3000\u5e02\u6c11\u5065\u5eb7\u306e\u3064\u3069\u3044. 2016.12(\u3064\u304f\u3070)<\/li>\n\n\n\n
                                            3. \u5927\u8c37\u5e79\u4f38. Female Patient\u2019s Insight. 2017.3(\u6c34\u6238)<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

                                              \u5e73\u621028\u5e74\u5ea6\uff5e\u5e73\u62106\u5e74\u5ea6 \u4ee4\u548c6\u5e74\u5ea6 \u3010\u8ad6\u6587\u3011 \u4ee4\u548c5\u5e74\u5ea6 \u3010\u8ad6\u6587\u3011 \u4ee4\u548c4\u5e74\u5ea6 \u3010\u8ad6\u6587\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u4ee4\u548c3\u5e74\u5ea6 \u3010\u57f7\u7b46\u3011 \u3010\u8ad6\u6587\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u4ee4\u548c2\u5e74\u5ea6 \u3010\u8ad6\u6587\u3011 \u3010\u5b66\u4f1a\u767a\u8868\u3011 \u3010\u53d7\u8cde\u3011 \u4ee4\u548c\u5143\u5e74 \u3010\u8457\u66f8\u3011 \u3010 […]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":796,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","vk-ltc-link":"","vk-ltc-target":"0"},"class_list":["post-16890","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16890","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/comments?post=16890"}],"version-history":[{"count":3,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16890\/revisions"}],"predecessor-version":[{"id":25104,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/16890\/revisions\/25104"}],"up":[{"embeddable":true,"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/pages\/796"}],"wp:attachment":[{"href":"https:\/\/www.hospital.pref.ibaraki.jp\/chuo\/wp-json\/wp\/v2\/media?parent=16890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}